<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100804">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01877759</url>
  </required_header>
  <id_info>
    <org_study_id>CSCC/BM/2013/LS/01</org_study_id>
    <nct_id>NCT01877759</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Evaluate the Safety and Efficacy of Mesenchymal Stem Cells in Liver Cirrhosis</brief_title>
  <official_title>Role of Bone Marrow Derived Autologous Stem Cells + Human Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Liver Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chaitanya Hospital, Pune</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chaitanya Hospital, Pune</source>
  <oversight_info>
    <authority>India: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cirrhosis is caused by sustained liver damage over several years either by alcohol, viral
      infection (Hepatitis B, C), a toxic substance (for eg. drugs, excess copper or iron in the
      liver), or by blockage of biliary system such that the liver undergoes progressive scarring
      that slowly replaces all of normal liver cells.(LC) represents a late stage of progressive
      hepatic fibrosis characterized by distortion of the hepatic architecture and formation of
      regenerative nodules. For this condition of disease the liver transplantation is one of the
      only effective therapies available ,but due to  lack of donors, surgical complications,
      rejection, and high cost are it`s serious problems.

      Presently stem cells are used to be a one of the treatment for the same. So our approach is
      to evaluate the safety and efficacy of mesenchymal stem cell in condition of liver cirrhosis
      .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the patients with liver cirrhosis will undergo administration of human
      Mesenchymal stem cell  MSCs intravenously for these patients.To observe the results  Liver
      function will be monitored by serum analysis.The levels of serum alanine aminotransferase
      (ALT), total bilirubin (TB), prothrombin time (PT), prealbumin(PA) and albumin (ALB) will be
      examined at pre-transfusion, and 6th  days to 1 years post-transfusion.Also the to see
      Improvement  evaluation by   MELD score ,Quality of life ,Child-Pugh score will be done .
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Improvement in Liver function tests</measure>
    <time_frame>6 month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>1)	Improvement of Liver Function tests liver functions( Albumin (ALB), Alanine aminotransferase (ALT), Aspartate Aminotransferase (AST), Prealbumin(PA), total bilirubin (TB), and direct bilirubin (DB) kidney function Blood urea nitrogen (BUN), Urea (UA), and Crea (Cr)),international normalized ratio (INR) in Liver Cirrhosis Patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in liver function according to Child-Pugh</measure>
    <time_frame>6 MONTH</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in liver function according to MELD Score</measure>
    <time_frame>6 MONTH</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in QUALITY OF LIFE SCALE (QOL)</measure>
    <time_frame>6 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes of any clinical symptoms like  abdominal distension, appetite, debilitation</measure>
    <time_frame>6 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Mesenchymal stem cell</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>hUMAN MESENCHYMAL STEM CELLS</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal stem cell</intervention_name>
    <description>Intravenous  dose of Mesenchymal stem cell derived from human Bone Marrow &amp; umbilical cord , IN 6 divided doses , at interval of 1 week .</description>
    <arm_group_label>Mesenchymal stem cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  25 -65 Ages Eligible for Study

          -  Clinical diagnosis of liver cirrhosis

          -  Ability to comprehend the explained protocol and thereafter give an informed consent
             as well as sign the required Informed Consent Form (ICF) for the study.

          -  Expecting lifetime is over three years

          -  Ready to come all visits

        Exclusion Criteria:

          -  History of life threatening allergic or immune-mediated reaction

          -  Positive test results for HIV and AIDS complex ,HCV , HbsAg and Syphilis

          -  Malignancies

          -  Sepsis

          -  Vital organs failure

          -  Pregnant or lactating women

          -  Subject who has been transplanted recently

          -  If the investigator or treating physician feels that the Subject with any disease or
             condition would interfere with the trial or the safety of patient
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ANANT E BAGUL, MS ORTHO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chaitanya Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sachin P Jamadar, D.Ortho</last_name>
    <phone>918888788880</phone>
    <email>sac2751982@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Smita S Bhoyar, B.A.M.S.PGCR</last_name>
    <phone>9372620569</phone>
    <email>drsmitabhoyar@rediff.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chaitanya Hospital</name>
      <address>
        <city>Pune,</city>
        <state>Maharashtra</state>
        <zip>411009</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sachin P Jamadar, D ORTHO</last_name>
      <phone>+918888788880</phone>
      <email>sac2751982@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Smita S Bhoyar, BAMS.PGCR</last_name>
      <phone>9372620569</phone>
      <email>drsmitabhoyar@rediffmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Anant E Bagul, MS,Ortho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 8, 2013</lastchanged_date>
  <firstreceived_date>June 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chaitanya Hospital, Pune</investigator_affiliation>
    <investigator_full_name>Dr. Sachin Jamadar</investigator_full_name>
    <investigator_title>Co -investigator</investigator_title>
  </responsible_party>
  <keyword>Stem cell ,liver cirrhosis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
